Next Phase Newsletter

The company is a NASDAQ-listed company that acquires, develops and commercializes promising drugs and technologies by forming and financing subsidiary companies. All subsidiary companies have access to resources necessary for cultivating and maintaining their business such as scientific, clinical, regulatory, manufacturing, legal and financial expertise. Among these key resources are committed investment capital, experienced start-up management with in-house Entrepreneurs in Residence (EIRs), world-class scientific expertise, and shared facilities. The company does not make equity only investments, but is open to a variety of deal structures to license, co-develop or acquire assets, including traditional milestone-based licensing deals, joint ventures, and option agreements with equity arrangements.

The company focuses primarily on therapeutic opportunities, but will also consider drug delivery devices/technologies. Current areas of interest include: – Late clinical stage or marketed dermatology programs/products – IND ready, clinical or marketed rare disease, oncology, neurology, opthamology, GI or Hepatology

The firm has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is a venture capital with offices in Massachusetts and California with approximately $1.8 billion under management. The firm is currently investing out of their third fund, a $825M fund that closed in the summer of 2021. The firm will make equity investments of approximately $40–60 million across all stages of private financing and can either lead investments or co-invest. The firm considers investment opportunities worldwide.

The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from preclinical (2–3 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.

The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong is currently managing two funds with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital group based out of Boston seeks to make seed and venture equity investments in early stage digital health related companies, focusing on Seed to Series A rounds. The firm is recently making a transition into digital health with their new fund. The firm typically allocates between $100k-$500k USD in their initial investment, but has the capability to invest large amounts as well (their LPs put in $40Million USD as a follow on to one of their investments). The firm also has the option of making follow-on investments and for companies they think would do well in China, has many resources in China that they can leverage for portfolio companies interested in operating in China. The firm is geographically agnostic, but prefers to invest in companies that are based in the US.

The firm is looking for companies in the digital health space or technologies that utilize/integrate software, AI, big data, virtual reality, or analytics within the healthcare field. The firm prefers companies that don’t have to go through regulatory hurdles. In terms of indication, the firm is agnostic so long as there is a basis in digital health. However, the firm currently has a particular interest in senior care related technologies given the recent need in China.

The firm prefers companies and teams with strong science behind their technology. They prefer, but do not require companies that have an interest in working in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Established in 2017, a venture capital fund is a new addition to its sister fund, a $60M+ venture capital partnership. The firm is focused on companies that contribute to the delivery of “Delightful Moments”, in other words technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. The firm has offices in USA and Western Europe, and expanded into Western Europe in early 2019. Currently, the firm is focused on investing in companies based in the USA and Western Europe.

The firm is interested in companies dedicated to the “technological vectors of happiness”. Such technologies include genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. Initially, the firm did not invest in traditional biopharmaceuticals or medical devices, but the firm has expanded their interests and now actively seeking opportunities in therapeutics and devices with a focus on early-stage, pre-IND companies.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A corporate venture arm of a large company specializing in infection prevention technology is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm Investments will invest globally.

The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection.

The firm will only make strategic investments that align with the company’s vision. The firm is an active investor, and will typically take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly founded venture capital firm headquartered in Europe with an additional office based in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stay away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.